Trade-Ideas LLC identified

OraSure Technologies

(

OSUR

) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified OraSure Technologies as such a stock due to the following factors:

  • OSUR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $6.3 million.
  • OSUR has traded 292,624 shares today.
  • OSUR is trading at 10.21 times the normal volume for the stock at this time of day.
  • OSUR is trading at a new low 4.10% below yesterday's close.

'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in OSUR with the Ticky from Trade-Ideas. See the FREE profile for OSUR NOW at Trade-Ideas

More details on OSUR:

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. OSUR has a PE ratio of 37. Currently there is 1 analyst that rates OraSure Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for OraSure Technologies has been 621,600 shares per day over the past 30 days. OraSure has a market cap of $373.4 million and is part of the health care sector and health services industry. The stock has a beta of 1.42 and a short float of 5% with 2.86 days to cover. Shares are up 9.8% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates OraSure Technologies as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, compelling growth in net income and reasonable valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:

  • OSUR's revenue growth has slightly outpaced the industry average of 6.9%. Since the same quarter one year prior, revenues slightly increased by 7.4%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • OSUR has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 5.85, which clearly demonstrates the ability to cover short-term cash needs.
  • This stock has managed to rise its share value by 16.80% over the past twelve months. Looking ahead, unless broad bear market conditions prevail, we still see more upside potential for this stock, despite the fact that it has already risen over the past year.
  • ORASURE TECHNOLOGIES INC has shown improvement in its earnings for its most recently reported quarter when compared with the same quarter a year earlier. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, ORASURE TECHNOLOGIES INC turned its bottom line around by earning $0.14 versus -$0.09 in the prior year. This year, the market expects an improvement in earnings ($0.19 versus $0.14).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 2064.6% when compared to the same quarter one year prior, rising from $0.11 million to $2.45 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.